IMCgp100

DRUG4 trials

Conditions

Malignant MelanomaUveal Melanoma

Phase 1

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

CompletedNCT01211262

Immunocore LtdMalignant Melanoma

Start: 2010-09-28End: 2017-02-16Updated: 2020-07-08

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

CompletedNCT02570308

Immunocore LtdUveal Melanoma

Start: 2016-02-29End: 2022-10-17Updated: 2023-03-21

Phase 2

IMCgp100-401 Rollover Study

TerminatedNCT02889861

Immunocore LtdMalignant Melanoma

Start: 2017-01-11End: 2019-04-22Updated: 2020-07-27

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

CompletedNCT03070392

Immunocore LtdUveal Melanoma

Start: 2017-10-16End: 2025-09-17Updated: 2026-03-17

Journal of Clinical Oncology2026-05-27

Abstract CT029: Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial

Cancer Research2026-04-17

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

Cell Reports Medicine2025-04-015 citations

Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp.

2025-03-241 citations

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.

2024-10-1415 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action

Journal of Investigative Dermatology2024-07-1515 citations

Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression.

Journal of Clinical Oncology2024-06-011 citations

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).

Journal of Clinical Oncology2024-06-01

Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.

Journal of Clinical Oncology2024-06-01

Abstract 1529: Development of lymphoid aggregates in metastatic uveal melanoma tumors treated with tebentafusp

Cancer Research2024-03-22

Abstract 4984: TCR-CD3 bispecifics kill tumor cells in a caspase- and gasdermin-dependent manner by inducing multiple cell death pathways

Cancer Research2024-03-22

Abstract IA005: Emerging insights from the tebentafusp clinical program

Molecular Cancer Therapeutics2023-12-01

30 Molecular features associated with long survival on tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial

Regular and Young Investigator Award Abstracts2023-10-31

1108 Novel regulators of ImmTAC-mediated killing of melanoma cancer cells revealed by genome-wide CRISPR-Cas9 screens

Regular and Young Investigator Award Abstracts2023-10-31

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

New England Journal of Medicine2023-10-21211 citations

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

Journal for ImmunoTherapy of Cancer2023-06-0123 citations

Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.

Journal of Clinical Oncology2023-06-015 citations

Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)

Cancer Research2023-04-14

Abstract 1035: Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

Cancer Research2023-04-042 citations

32 more papers not shown

IMCgp100

Sponsors

Conditions

Phase 1

Phase 2

Related Papers